Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mirtazapine
Drug ID BADD_D01476
Description Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994.[A177946] This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.[A177811]
Indications and Usage For the treatment of major depressive disorder.
Marketing Status Prescription; Discontinued
ATC Code N06AX11
DrugBank ID DB00370
KEGG ID D00563
MeSH ID D000078785
PubChem ID 4205
TTD Drug ID D05ZIK
NDC Product Code 78206-156; 38779-3076; 68084-121; 63187-471; 43353-963; 55154-5355; 71052-108; 70600-004; 57664-510; 63187-403; 72969-049; 57237-009; 68071-4989; 57237-007; 63629-2367; 71335-1534; 68071-4972; 65862-001; 58032-0121; 65862-021; 57237-008; 0904-6519; 57237-011; 50090-4643; 58118-0052; 53002-2712; 43353-378; 60687-584; 12860-0076; 70518-1397; 68084-119; 53296-0047; 43353-962; 13107-003; 50090-5296; 65862-003; 68788-7754; 55154-7297; 50090-4222; 71610-115; 49999-629; 68071-2635; 51407-350; 13107-031; 17856-0101; 71610-475; 63629-3346; 43353-535; 51407-351; 50090-1057; 53002-1474; 71610-523; 57237-013; 57237-012; 13107-001; 57237-010; 0378-3545; 0615-8078; 65862-032; 68788-7324; 65862-022; 68084-120; 78206-160; 71335-0542; 65862-031; 71610-121; 0378-3515; 0615-8268; 78206-159; 63187-554; 63629-2366; 70518-2453; 78206-158; 70518-2819; 55154-8145; 55154-8335; 57664-499; 71610-369; 71335-0664; 60312-0096; 63739-098; 65862-023; 71335-0441; 68071-4379; 50090-2140; 70518-2582; 68788-7492; 51407-352; 50090-2558; 0615-8269; 43353-536; 57664-500; 71335-0964; 71610-100; 51079-088; 63739-099; 53002-1712; 13107-032; 70518-1838; 55700-249; 71335-0372; 12860-0077; 60870-0117; 50090-2800; 51079-086; 60505-0247; 70518-1293; 71335-0286; 78206-161; 51079-087; 45865-382; 68071-4752; 60505-0249; 12860-0030; 68071-4239; 63629-2368; 68071-4539; 70518-1309; 63629-5537; 63629-5086; 57664-501; 71335-0122; 63187-206; 45865-137; 71335-1332; 50090-4123; 0378-3530; 60312-0095; 71205-481; 71335-0717; 60505-0248
Synonyms Mirtazapine | 6-Azamianserin | 6 Azamianserin | ORG 3770 | ORG-3770 | ORG3770 | Rexer | Remeron | Norset | Remergil | Zispin | Esmirtazapine | (S)-Mirtazapine | Org 50081 | (N-Methyl-11C)mirtazapine
Chemical Information
Molecular Formula C17H19N3
CAS Registry Number 85650-52-8
SMILES CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatic cirrhosis09.01.04.001--Not Available
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.001--Not Available
Hepatic steatosis14.08.04.005; 09.01.07.0030.000143%Not Available
Hepatitis09.01.07.0040.002189%Not Available
Hepatitis acute09.01.07.0050.000730%Not Available
Hepatitis toxic12.03.01.016; 09.01.07.0170.000730%Not Available
Hepatocellular injury09.01.07.0080.001277%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.000547%Not Available
Herpes simplex23.09.03.001; 11.05.02.001--Not Available
Herpes zoster23.09.03.002; 11.05.02.003--
Hiatus hernia22.09.02.004; 07.16.01.0010.000365%Not Available
Hiccups22.02.04.002; 07.01.06.009--
Hostility19.05.01.0030.000547%Not Available
Hunger14.03.02.012; 08.01.09.0030.000365%Not Available
Hyperacusis17.04.03.003; 04.02.02.001--Not Available
Hyperaesthesia17.02.06.0040.000365%Not Available
Hyperbilirubinaemia01.06.04.003; 14.11.01.010; 09.01.01.0030.000912%Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.0020.001459%
Hyperhidrosis23.02.03.004; 08.01.03.0280.006566%
Hyperkalaemia14.05.03.0010.000730%
Hyperkinesia17.01.02.0080.000547%Not Available
Hyperprolactinaemia05.03.01.0020.000365%Not Available
Hyperreflexia17.02.01.0020.000365%Not Available
Hypersensitivity10.01.03.003--
Hypertension24.08.02.0010.002736%
Hyperthermia malignant08.05.01.0020.000365%Not Available
Hypertonia17.05.02.001; 15.05.04.0070.000912%Not Available
Hypertriglyceridaemia14.08.02.0010.001094%
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 23 Pages